Targeted Chorea Management: Primarily indicated for the symptomatic treatment of chorea (uncontrolled, jerky, involuntary movements) associated with Huntington's disease.

Controls Hyperkinetic Movements: Helps to reduce the severity and frequency of various hyperkinetic movement disorders by balancing certain chemicals in the brain.

Specific Mechanism of Action: Works as a reversible inhibitor of the vesicular monoamine transporter type 2 (VMAT-2), leading to a controlled depletion of monoamine neurotransmitters (like dopamine) in the central nervous system.

Adjunct Therapy: Can be a key part of the comprehensive management plan for Huntington's disease, focusing specifically on motor symptoms.